acute myeloid leukemia (aml): the role of maintenance chemo¬therapy
Authors
abstract
maintenance treatment for patients with acute myeloid leukemia (aml) in remission has recently been controversially discussed and even abandoned by several groups. an analysis of 16 published multicenter trials, however, revealed the highest probabilities of relapse free survival (rfs) in the range of 35-42 % at 4-5 years only in patients assigned to maintenance treatment when adult age and intent-to-treat conditions were considered. after having demonstrated a superior rfs from 3 year maintenance following standard dose consolidation over that from consolidation alone (p<0.0001), the german amlcg requestioned the effect of maintenance randomly compared with sequential high-dose arac and mitoxantrone (s-ham) in patients having received intensified induction treatment. the rfs shows an advantage for maintenance with 32 % versus 25 % (p= .021). we conclude that maintenance treatment continues to substantially contribute to the management of adult patients with aml, even as part of recent strategies using intensified induction treatment, and thus appears necessary in these settings.
similar resources
acute myeloid leukemia (aml): the role of intensive induction chemotherapy
intensive induction therapy-in acute myeloid leukemia (aml), as in some other systemic malignancies- is a strategy fundamentally different from post-remission strategies. approaches like consolidation treatment, prolonged mainte nance, and autologous or allogeneic transplantation in the first remission are directed against minimal residual disease with a malignant cell population having survive...
full textThe role of microRNA in acute/chronic, myeloid/lymphocytic leukemia
MicroRNAs are small, non-coding sequences that regulate gene expression by inducing degradation or translational inhibition of target mRNAs. These molecules control many intracellular physiological and pathological processes.Abnormal expression of these moleculs has been described in different cancers including hematopoietic cancers. According to the type of cancer and the stage, miRNA’s expres...
full textChromosomal rearrangements in acute myeloid leukemia (AML)
E Belloni, M Trubia, P Gasparini, C Micucci, C Tapinassi, S Confalonieri, P Nuciforo, B Martino, F Lo-Coco, PP Di Fiore and PG Pelicci Istituto Europeo di Oncologia, Milan, Italy Campus IFOM-IEO, Milan, Italy Divisione di Ematologia, Azienda Ospedaliera Bianchi-Malacrino-Morelli, Reggio Calabria, Italy Università di Roma Tor Vergata, Department of Biopatologia e Diagnostica per Immagini, Rome, ...
full textEffective Dendritic Cell-based Immunotherapeutic Vaccines for Acute Myeloid Leukemia (AML)
Acute myeloid leukemia (AML) is a type of poor prognosis hematological malignancies characterized by heterogeneous clonal expansion of myeloid progenitors. Leukemic stem cells are thought to form the majority of a cell population in minimal residual diseases (MRDs) which are resistant to current chemotherapeutic regimens and mediate disease relapse. Current therapeutic vaccine strategies have d...
full textOccurrence of Secondary Acute Myeloid Leukemia in a Patient with Breast Cancer after Chemotherapy
full text
Induction Chemotherapy for Acute Myeloid Leukemia – Experiences from the AML-CG Studies
O ver the last three decades the overall prognosis of patients suffering from AML has steadily improved. Nowadays, complete remissions are achieved in 60 – 70% of all patients with long-term disease free survival and potential cure in 25 – 40% of cases. A more detailed analysis indicates that this progress has mainly been achieved in patients <60 years of age while in older patients little impr...
full textMy Resources
Save resource for easier access later
Journal title:
international journal of hematology-oncology and stem cell researchجلد ۱، شماره ۱، صفحات ۶-۱۱
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023